Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02604641
Other study ID # Q10 01-2014
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2014
Est. completion date May 2015

Study information

Verified date October 2021
Source Higher School of Applied Sciences (VIST)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Objective of the study is to determine the influence of dietary supplementation with coenzyme Q10 (CoQ10) on skin conditions. 33 healthy female subjects will be randomly assigned to a placebo group, a low-dose (LD) group receiving 50 mg CoQ10/day and a high-dose group (HD) receiving 150 mg CoQ10/day (11 subjects per group). A water-soluble form of CoQ10 with improved bioavailability (Quvital syrup with Q10vital®, Valens Int. d.o.o., Slovenia) will be used. Various skin parameters will be evaluated before the supplementation (the baseline), after 6 and after 12 weeks of supplementation. To evaluate the photoprotective potential of CoQ10 the minimal erythema dose (MED) will be determined before (the baseline) and after 12 weeks of the supplementation.


Description:

Objective of the study is to determine the influence of dietary supplementation of CoQ10 in form of water-soluble Q10vital® on skin conditions. 33 healthy female subjects will be randomly assigned to a placebo group, a low-dose (LD) group receiving 50 mg CoQ10/day and a high-dose group (HD) receiving 150 mg CoQ10/day (11 subjects per group). A water-soluble form of CoQ10 with improved bioavailability (Quvital syrup with Q10vital®, Valens Int. d.o.o., Slovenia) will be used. The placebo or CoQ10 will be administered in the form of a syrup; all subjects will consume 5 mL of syrup daily for 12 weeks. The photoprotective potential of CoQ10 will be evaluated with a determination of the minimal erythema dose (MED) before (the baseline) and after 12 weeks of the supplementation. Other skin parameters will be evaluated before supplementation (the baseline), after 6 and after 12 weeks of supplementation. Comparison will be done as the mean of the individual ratios. The differences between the before-after condition will be analyzed with the statistical test of analysis of variance. In case of failure to find homogeneity in the variances the nonparametric ANOVA, the Willcoxon test, will be used. The results will be expressed as mean ± standard error for each group with a significance level of 0.05 for all the statistical tests.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date May 2015
Est. primary completion date May 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 45 Years to 60 Years
Eligibility Inclusion Criteria: - Signs of skin aging (mimic wrinkles/ poor skin tone/ visual dryness), - Photoaged skin on the face, - Expression of mimic wrinkles, - Phototype II and III. Exclusion Criteria: - Allergy to ingredients of tested products - High blood cholesterol and use of cholesterol-lowering medicines, - Diagnosed diabetes - Thyroid disease - Inflammatory skin diseases, - Regular use of dietary supplements 6 months or less before start of the study, - Invasive rejuvenation treatments (botox injections, hyaluronic acid fillers, needle rollers, needle mesotherapy, etc.) 6 months or less prior to start of the study, - Non-invasive rejuvenation treatments (radiofrequency, electrotherapy, ultrasound therapy, no-needle mesotherapy, etc.) 6 months or less prior to start of the study, - The use of cosmetic products containing coenzyme Q10 6 months or less prior to start of the study, - Gluteal hyperpigmentation, - Expected sunbathing (also in solariums) within the study period.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Placebo group
Subjects will take 5 mL of placebo syrup (0 mg CoQ10/day) once per day for 12 weeks.
Quvital LD group
Subjects will take 5 mL of LD syrup (50 mg CoQ10/day) once per day for 12 weeks.
Quvital HD group
Subjects will take 5 mL of LD syrup (150 mg CoQ10/day) once per day for 12 weeks.

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Higher School of Applied Sciences (VIST) Nutrition Institute, Slovenia, Valens Int. d.o.o., Slovenija

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement of photoprotective function of the skin Minimal erythema dose (MED) of the skin will be determined. Skin on gluteal part of the body will be exposed to 10 different doses of UVB light and 24 hours after exposure MED will be determined.Higher MED indicates better photoprotective function of the skin. after 12 weeks of the supplementation
Secondary Reduction of the area of the periorbital facial wrinkles Area of selected periorbital wrinkles will be quantitatively assessed using CSI programme. after 6 and after 12 weeks of the supplementation
Secondary Reduction of the volume of the periorbital facial wrinkles Volume of selected periorbital wrinkles will be quantitatively assessed using CSI programme. after 6 and after 12 weeks of the supplementation
Secondary Reduction of wrinkles at different face areas Expert assessment of wrinkles at different face areas (periorbital, frontal, glabelar, nasolabial areas etc.) will be done according to Lemperle Wrinkle assessment scale. after 6 and after 12 weeks of the supplementation
Secondary Improvement of the dermis structure Ultrasound (US) images of the dermis will be taken and intensity of the dermis determined. Higher intensity of the dermis US images indicates improvement of the collagen and elastin network. after 6 and after 12 weeks of the supplementation
Secondary An increase of the dermis thickness Dermis thickness will be measured with ultrasound imaging of the skin. after 6 and 12 weeks of the supplementation
See also
  Status Clinical Trial Phase
Completed NCT01984619 - Prospective Study Evaluating the Treatment of Hyperdynamic Forehead Wrinkles N/A
Completed NCT01713985 - Feasibility Study: Evaluation of Ulthera Versus Thermage for Treating the Face and Neck N/A
Recruiting NCT01586819 - Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A Phase 3
Completed NCT05254210 - Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device N/A
Completed NCT01519934 - A Retrospective Study to Evaluate the Effectiveness of the Ulthera System N/A
Completed NCT01460927 - TriActive+ Radiofrequency (RF) for Non-invasive Treatment of Wrinkles & Rhytides N/A
Completed NCT03811756 - The Effect of 12-week Dietary Intake of Syrup Containing CoQ10 and Collagen on Dermis Density and Other Skin Parameters N/A
Completed NCT04988412 - The Effect of 12-week Dietary Intake of Food Supplements Containing Collagen on Dermis Density and Other Skin Parameters N/A
Completed NCT02913547 - Silk'n HST for Wrinkle Reduction - Clinical Study Protocol N/A
Active, not recruiting NCT02019004 - A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles N/A
Completed NCT02340078 - A Clinical Study to Evaluate the Efficacy and Safety of YVOIRE Volume Plus Versus YVOIRE Volume in Nasolabial Fold Injection N/A
Completed NCT01283464 - Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles Phase 2
Completed NCT01034956 - Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections N/A
Completed NCT02425943 - Sculptra Aesthetic Post-Approval Study Phase 4
Recruiting NCT05847530 - Pilot Evaluation of the Cynosure Potenza™ System for Treatment of Cosmetic Dermatologic Skin Conditions N/A
Enrolling by invitation NCT01847066 - Epidermal Delivery of Ani-Aging Ingredients N/A
Completed NCT01859611 - TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and Rhytides N/A
Completed NCT01297634 - Radial Diffusion of the Botulinum Toxin Type A (Botox®): Electromyographic Evaluation of the Frontal Muscle Phase 4
Completed NCT05011461 - The Effect of Topical Almond Oil vs. Topical Retinol on The Appearance of Facial Wrinkles N/A
Completed NCT03460860 - Astaxanthin (2 mg) + Lycopene (1.8 mg) + D-Alpha-Tocopherol (10 IU) For The Treatment Of Skin Aging N/A